货号:A645681
同义名:
YM477; AKR-501
Avatrombopag is an orally-active thrombopoietin (TPO) receptor agonist with EC50 of 3.3 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist with an EC50 of 3.3 nM. It mimics the biological activities of TPO, stimulating platelet production by activating the intracellular signaling system and promoting the generation of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag is metabolized by cytochrome P450 (CYP) 2C9 and CYP3A enzymes [1][2][3]. |
Animal study | Avatrombopag (0.3-3 mg/kg; pO.; daily for 14 days) enhances human platelet count in NOD/SCID mice that have been transplanted with human FL CD34+ cells [1]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.54mL 0.31mL 0.15mL |
7.70mL 1.54mL 0.77mL |
15.39mL 3.08mL 1.54mL |
CAS号 | 570406-98-3 |
分子式 | C29H34Cl2N6O3S2 |
分子量 | 649.65 |
SMILES Code | O=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5CCN(C6CCCCC6)CC5)S3)=O)C=C2Cl)CC1)O |
MDL No. | MFCD18633249 |
别名 | YM477; AKR-501; AS 1670542; E5501 |
运输 | 蓝冰 |
InChI Key | OFZJKCQENFPZBH-UHFFFAOYSA-N |
Pubchem ID | 9852519 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |